ADC Therapeutics Announces Participation at 2025 Cantor Global Healthcare Conference

ADC Therapeutics at the Cantor Global Healthcare Conference 2025

ADC Therapeutics SA, a leader in the field of antibody drug conjugates (ADCs), is excited to announce the participation of CEO Ameet Mallik in a fireside chat at the highly anticipated Cantor Global Healthcare Conference 2025. This event is set to take place on September 3, 2025, at 9:10 a.m. ET. The conference serves as a significant platform for industry leaders to discuss advancements, share insights, and connect with investors.

During the conference, attendees can look forward to an engaging dialogue that highlights ADC Therapeutics' innovative contributions to cancer therapies. The focus will be on ZYNLONTA (loncastuximab tesirine-lpyl), a critical treatment option that has received accelerated approval from the FDA and conditional approval from the European Commission for patients with relapsed or refractory diffuse large B-cell lymphoma following at least two lines of systemic therapy.

Overview of ADC Therapeutics

Headquartered in Lausanne, Switzerland, ADC Therapeutics operates with a commitment to transforming cancer treatment through pioneering ADC technology. The company’s portfolio includes ZYNLONTA and a promising investigational PSMA-targeting ADC designed to target prostate-specific membrane antigen. With a focus on leveraging advanced payload technologies paired with unique linkers, ADC Therapeutics aims to innovate the delivery of therapeutics while minimizing toxicity and maximizing efficacy.

The fireside chat is expected to spotlight the future direction of ADC Therapeutics as it navigates the complexities of cancer treatments. By harnessing their specialized capabilities from clinical trials to market launch, the company is poised to address growing demands within oncology.

Additionally, a live webcast of the presentation will be accessible on the Events & Presentations page within the Investors section of the ADC Therapeutics website. For those unable to attend live, a replay will be available for 30 days post-event.

Looking Ahead

Looking to the future, ADC Therapeutics continues to mobilize its robust research and development efforts, with several upcoming trials that may lead to significant breakthroughs in cancer treatment. Given the recent developments, investors and members of the healthcare community eagerly anticipate the upcoming announcements from the company.

It's important to note that the statements made during the conference may include forward-looking elements that involve uncertainties and risks, underscoring the dynamic nature of the biotech industry and the broader healthcare landscape. Stakeholders are encouraged to consider the various factors that could contribute to deviations from anticipated results.

To learn more about ADC Therapeutics' groundbreaking work and to stay updated on their initiatives, visit their website at adctherapeutics.com and follow their progress on LinkedIn. As ADC Therapeutics prepares to engage with the community at the Cantor Global Healthcare Conference, the emphasis on innovation in cancer treatments has never been more prominent.

For media inquiries or further information, please contact Nicole Riley, who represents ADC Therapeutics, at [email protected] or call +1 862-926-9040.

Stay tuned for developments from ADC Therapeutics as they lead the charge in transforming cancer care through antibody drug conjugates.